JAZZ•benzinga•June 2, 2025 at 08:09 PM

Jazz Pharmaceuticals Announces Phase 3 IMforte Trial Results Showing Zepzelca Plus Atezolizumab First-Line Maintenance Therapy Reduces Disease Progression Risk By 46% And Extends Median Overall Survival To 13.2 Months In ES-SCLC; Data Presented At ASCO 20

No summary available.

Read the full article from the original source for complete details and context.

Article published on June 2, 2025 by benzinga